PulmCCM

PulmCCM

Share this post

PulmCCM
PulmCCM
The Latest in Critical Care, 7/10/23 (Issue #8)
Copy link
Facebook
Email
Notes
More

The Latest in Critical Care, 7/10/23 (Issue #8)

Jul 10, 2023
∙ Paid
13

Share this post

PulmCCM
PulmCCM
The Latest in Critical Care, 7/10/23 (Issue #8)
Copy link
Facebook
Email
Notes
More
Share

Continuous meropenem infusion for critically ill patients with sepsis (MERCY trial)

PulmCCM
·
July 16, 2023
Continuous meropenem infusion for critically ill patients with sepsis (MERCY trial)

Antibiotics have a time-dependent effect on bacteria, so maintaining bacteriocidal concentrations of antibiotics should theoretically help subdue infections better than intermittent dosing. A 2018 meta-analysis reviewed here suggested that prolonged infusion of antipseudomonal beta-lactams reduced mortality by 30% compared with shorter infusions, and mo…

Read full story

When to start anticoagulation after ischemic stroke from atrial fibrillation

PulmCCM
·
June 16, 2024

It’s been unclear when to start anticoagulation after an ischemic stroke presumed due to thromboembolism from atrial fibrillation. There’s a period of time after ischemic stroke when damaged cerebral blood vessels are susceptible to bleeding. Anticoagulation during this vulnerable period could result in so-called hemorrhagic transformation, worsening b…

Read full story

Should platelets be transfused in thrombocytopenic patients before central line placement?

PulmCCM
·
June 16, 2024

Central venous catheterization (CVC or central lines), when placed with ultrasound guidance, have a low rate of severe bleeding complications, even in patients with significant thrombocytopenia. Nevertheless, platelets are frequently transfused prior to CVC placement in patients with platelet counts 20,000-50,000/mcL. Is this justified?

Read full story

In The News

FDA approved the new intravenous antibiotic sulbactam-durlobactam (Xacduro) for healthcare-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus complex (A. baumannii). Sulbactam is a beta-lactam and durlobactam a beta-lactamase inhibitor. Carbapenem-resistant Acinetobacter infections increased by almost 80% between 2019 and 20…

Keep reading with a 7-day free trial

Subscribe to PulmCCM to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 PulmCCM LLC
Publisher Terms
Substack
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More